Genetico Center (Genetics and Reproductive Medicine Center, MOEX: GECO) has published an analytical review of the global non-invasive prenatal testing (NIPT) markets.
The global NIPT market was estimated at USD 3.66 billion in 2022 (Reaserch and Market). It is expected to USD 6.95 billion by 2028, with a compound annual growth rate (CAGR) of 9.6%.
In 2023, Genetico Center received Roszdravnadzor’s permit to use the Prenetix test kit developed in Genetico’s NIPT laboratory. This was the first test registered under Decree of the Government of the Russian Federation No. 2026 dated 11/24/2021. Health care institutions now can legally provide prenatal screening services using Prenetix and purchase the test kit through government procurement.
Genetico Center calculated that about 30,000 NIPT tests were conducted in Russia in 2022. Russia’s NIPT market amounted to approximately USD 11.28 million in 2022. With such numbers, service penetration is only 3%. The data indicates high potential for market development. Today, NIPT is paid for by the end consumer in Russia. If NIPT is introduced into compulsory medical insurance as a second or first-line test, the penetration of the service in Russia may increase exponentially and gradually reach the levels of Belgium and the Netherlands of over 50-75%.
NIPT is a safe non-invasive test that helps to accurately determine the risk of fetal chromosomal abnormalities as early as in the 10th week of pregnancy. The test does not require fetal tissues to be collected as with invasive testing, venous blood from the expectant mother is enough. Today, NIPT is one of the most convenient, accurate and safe methods of obtaining information on the potential risk of chromosomal abnormalities of the fetus in early pregnancy. The accuracy of the method is up to 99%. Researchers note that NIPT is superior to all other traditional screening methods and provides more accurate results for trisomy 21 (Down syndrome).
Genetico Center was one of the first companies to introduce NIPT into medical practice in 2014. In 2017, Genetico opened a laboratory in Moscow where they localized the Prenetix technology. The laboratory was created with the support of the Industrial Development Fund of the Ministry of Industry and Trade, the Russian Venture Company Biofund and the Agency for Strategic Initiatives.
In some countries, NIPT is used as a first-line test and the government fully funds NIPT for all pregnant women. For example, in Belgium, where a similar program has been in place since 2017, the service is provided to more than 75% of pregnant women.
In the Netherlands, NIPT has been a first-line test since 2017. It is partially or fully funded by the government and performed in about 50% of pregnant women.
In China, about 2.6 million NIPT tests were performed in 2022, indicating the service penetration level of 28%.
Genetico Center is an Artgen Biotech company (ex. Human Stem Cell Institute (HSCI: MOEX: ISKJ). A resident of Skolkovo and Technopark Medtech. The company works in the field of medical genetics and genetic research, implementing into medical practice innovative solutions for the diagnosis, prevention, and treatment of genetic and socially significant diseases. Genetico’s shares are traded in the IIM (Innovation and Investment Market) sector, the exchange sector for high-tech companies with significant growth potential. Genetico’s shares are listed as high-tech economy sector securities.